Trial Profile
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SWOG S1403
- 07 Feb 2024 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 08 Jul 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.
- 14 Dec 2022 Planned End Date changed from 12 Oct 2022 to 15 Jun 2023.